Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.23%
$25.84
0% positive prob.
5-Day Prediction
-2.01%
$25.27
0% positive prob.
20-Day Prediction
-3.05%
$25.00
0% positive prob.
SEC 8-K filings with transcript text
Feb 3, 2026 · 100% conf.
1D
+0.23%
$25.84
Act: +4.46%
5D
-2.01%
$25.27
Act: +7.08%
20D
-3.05%
$25.00
Act: +3.12%
pfe-202602030000078003false00000780032026-02-032026-02-030000078003us-gaap:CommonStockMember2026-02-032026-02-030000078003pfe:NotesDue20271.000Member2026-02-032026-02-030000078003pfe:NotesDue20292.875Member2026-02-032026-02-030000078003pfe:NotesDue20323.250Member2026-02-032026-02-030000078003pfe:NotesDue20373.875Member2026-02-032026-02-030000078003pfe:NotesDue20454.250Member2026-02-032026-02-03
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): February 3, 2026
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029
New York Stock Exchange 3.250% Notes due 2032
New York Stock Exchange 3.875% Notes due 2037
New York Stock Exchange 4.250% Notes due 2045
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: February 3, 2026
Nov 4, 2025
pfe-202511040000078003false00000780032025-11-042025-11-040000078003us-gaap:CommonStockMember2025-11-042025-11-040000078003pfe:NotesDue20271.000Member2025-11-042025-11-040000078003pfe:NotesDue20292.875Member2025-11-042025-11-040000078003pfe:NotesDue20323.250Member2025-11-042025-11-040000078003pfe:NotesDue20373.875Member2025-11-042025-11-040000078003pfe:NotesDue20454.250Member2025-11-042025-11-04
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 4, 2025
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27 New York Stock Exchange 2.875% Notes due 2029
New York Stock Exchange 3.250% Notes due 2032
New York Stock Exchange 3.875% Notes due 2037
New York Stock Exchange 4.250% Notes due 2045
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated November 4, 2025, reporting Pfizer’s financial results for the third quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: November 4, 2025
Aug 5, 2025
pfe-202508050000078003false00000780032025-08-052025-08-050000078003us-gaap:CommonStockMember2025-08-052025-08-050000078003pfe:NotesDue20271.000Member2025-08-052025-08-050000078003pfe:NotesDue20292.875Member2025-08-052025-08-050000078003pfe:NotesDue20323.250Member2025-08-052025-08-050000078003pfe:NotesDue20373.875Member2025-08-052025-08-050000078003pfe:NotesDue20454.250Member2025-08-052025-08-05
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 5, 2025
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE/27New York Stock Exchange 2.875% Notes due 2029
New York Stock Exchange 3.250% Notes due 2032
New York Stock Exchange 3.875% Notes due 2037
New York Stock Exchange 4.250% Notes due 2045
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 5, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated August 5, 2025, reporting Pfizer’s financial results for the second quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated August 5, 2025, reporting Pfizer’s financial results for the second quarter of 2025.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: August 5, 2025
Apr 29, 2025
pfe-202504290000078003false00000780032025-04-292025-04-290000078003us-gaap:CommonStockMember2025-04-292025-04-290000078003pfe:NotesDue20271.000Member2025-04-292025-04-29
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): April 29, 2025
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On April 29, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 2.05 Cost Associated with Exit or Disposal Activities On April 29, 2025, Pfizer announced approximately $1.2 billion of additional anticipated savings associated with its ongoing cost realignment program (the “Realigning Our Cost Base Program” or the “Program”) expected to be achieved by the end of 2027, designed to further reduce costs primarily in selling, information and administrative expenses (“SI&A”) driven in large part by enhanced digital enablement, including automation and artificial intelligence (“AI”), and simplification of business processes. Pfizer expects one-time costs to achieve the additional savings to be incurred through 2027 and to total approximately $1.6 billion, primarily representing cash expenditures for severance, digital enablement and implementation. Pfizer announced that it remains on track to deliver net cost savings of approximately $4.5 billion by the end of 2025, and, with the additional targeted savings, Pfizer now expects total net cost savings of approximately $5.7 billion from this program through 2027.(1) In addition, in connection with Pfizer’s efforts to simplify the structure and sharpen the focus of its research and development (“R&D”) organization, in the first quarter of 2025 Pfizer expanded the Program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. Savings associated with the simplification of the company’s R&D organization are anticipated to be realized by the end of 2026 and are expected to total approximately $500 million and be reinvested in R&D programs. Pfizer expects one-time costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing ca
Feb 4, 2025
pfe-202502040000078003false00000780032025-02-042025-02-040000078003us-gaap:CommonStockMember2025-02-042025-02-040000078003pfe:NotesDue20271.000Member2025-02-042025-02-04
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): February 4, 2025
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated February 4, 2025, reporting Pfizer’s financial results for fourth-quarter and full-year 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated February 4, 2025, reporting Pfizer’s financial results for fourth-quarter and full-year 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: February 4, 2025
Oct 29, 2024
pfe-202410290000078003false00000780032024-10-292024-10-290000078003us-gaap:CommonStockMember2024-10-292024-10-290000078003pfe:NotesDue20271.000Member2024-10-292024-10-29
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): October 29, 2024
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 29, 2024, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated October 29, 2024, reporting Pfizer’s financial results for the third quarter of 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated October 29, 2024, reporting Pfizer’s financial results for the third quarter of 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: October 29, 2024
Jul 30, 2024
pfe-202407300000078003false00000780032024-07-302024-07-300000078003us-gaap:CommonStockMember2024-07-302024-07-300000078003pfe:NotesDue20271.000Member2024-07-302024-07-30
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): July 30, 2024
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On July 30, 2024, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated July 30, 2024, reporting Pfizer’s financial results for the second quarter of 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated July 30, 2024, reporting Pfizer’s financial results for the second quarter of 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: July 30, 2024
May 1, 2024
pfe-202405010000078003false00000780032024-05-012024-05-010000078003us-gaap:CommonStockMember2024-05-012024-05-010000078003pfe:NotesDue20271.000Member2024-05-012024-05-01
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): May 1, 2024
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 1, 2024, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated May 1, 2024, reporting Pfizer’s financial results for the first quarter of 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated May 1, 2024, reporting Pfizer’s financial results for the first quarter of 2024.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: May 1, 2024
Jan 30, 2024
pfe-202401300000078003false00000780032024-01-302024-01-300000078003us-gaap:CommonStockMember2024-01-302024-01-300000078003pfe:NotesDue20271.000Member2024-01-302024-01-30
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): January 30, 2024
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On January 30, 2024, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated January 30, 2024, reporting Pfizer’s financial results for fourth-quarter and full-year 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated January 30, 2024, reporting Pfizer’s financial results for fourth-quarter and full-year 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: January 30, 2024
Dec 14, 2023
8-K
PFIZER INC false 0000078003 0000078003 2023-12-14 2023-12-14 0000078003 us-gaap:CommonStockMember 2023-12-14 2023-12-14 0000078003 us-gaap:DeferrableNotesMember 2023-12-14 2023-12-14
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
Date of report (Date of earliest event reported): December 14, 2023
(Exact name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
66 Hudson Boulevard East New York, New York
10001-2192 (Zip Code)
(Address of principal executive offices) Registrant’s telephone number, including area code: (212) 733-2323 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.05 par value
PFE
New York Stock Exchange
1.000% Notes due 2027
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01 Completion of Acquisition or Disposition of Assets.
Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 12, 2023, by and among Pfizer Inc., a Delaware corporation (“Pfizer”), Aris Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pfizer (“Merger Sub”), and Seagen Inc., a Delaware corporation (“Seagen”), Merger Sub was merged with and into Seagen (the “Merger”), with Seagen surviving the Merger as a wholly owned subsidiary of Pfizer. The Merger became effective on December 14, 2023 (the “Effective Time”). At the Effective Time, each issued and outstanding share of Seagen common stock, par value $0.001 per share (the “Seagen Shares”), was converted into the right to receive (without interest) $229.00 in cash (the “Merger Consideration”), subject to limited exceptions set forth in the Merger Agreement, and each outstanding Seagen equity award was either converted into the right to receive the Merger Consideration for each share of Seagen common stock underlying such awards (based on the achievement of any applicable performance metrics as set forth in the Merger Agreement), less applicable tax withholdings, or converted into a Pfizer cash-based award otherwise remaining subject to substantially the same terms and conditions applicable to such Seagen equity award immediately prior to the effective time of the Merger, in each case subject to the terms and conditions of the Merger Agreement. The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which was filed as Exhibit 2.1 to Pfizer’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 13, 2023, and is incorporated by reference into this Item 2.01.
Item 7.01 Regulation FD Disclosure.
On December 14, 2023, Pfizer issued a press release announcing the successful completion of the Merger. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 7.01. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Description
2.1
Oct 31, 2023
pfe-202310310000078003false00000780032023-10-312023-10-310000078003us-gaap:CommonStockMember2023-10-312023-10-310000078003pfe:NotesDue20271.000Member2023-10-312023-10-31
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): October 31, 2023
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 31, 2023, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated October 31, 2023, reporting Pfizer’s financial results for the third quarter of 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated October 31, 2023, reporting Pfizer’s financial results for the third quarter of 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: October 31, 2023
Oct 13, 2023
pfe-202310130000078003false00000780032023-10-132023-10-130000078003us-gaap:CommonStockMember2023-10-132023-10-130000078003pfe:NotesDue20271.000Member2023-10-132023-10-13
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): October 13, 2023
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On October 13, 2023, Pfizer Inc. (“Pfizer” or the “Company”) issued a press release providing an update to Pfizer’s previously issued guidance for full year 2023 and other information regarding the Company’s performance in the third quarter of 2023. A copy of the press release is furnished as Exhibit 99 hereto and is incorporated herein by reference.
The information furnished pursuant to this “Item 2.02 – Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 2.05. Costs Associated with Exit or Disposal Activities.
In the fourth quarter of 2023, Pfizer announced that, to realign Pfizer’s costs with its longer-term revenue expectations, Pfizer launched a multi-year, enterprise-wide cost realignment program (the “Cost Realignment Program”).
The Cost Realignment Program is expected to deliver targeted savings of at least $3.5 billion, of which $1.0 billion is expected to be realized in 2023 and an additional $2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the Cost Realignment Program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. The estimate of costs that Pfizer expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ from current expectations. Pfizer may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Cost Realignment Program.
Item 7.01. Regulation FD Disclosure.
On October 13, 2023, Pfizer issued a press release regarding, among other things, an amended supply agreement with the U.S. government for Paxlovid and the preceding items. A copy of the press release is furnished as Exhibit 99 hereto and is incorporated herein by reference.
The information furnished pursuant to this “Item 7.01 – Regulation FD Disclosure”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by ref
Aug 1, 2023
pfe-202308010000078003false00000780032023-08-012023-08-010000078003us-gaap:CommonStockMember2023-08-012023-08-010000078003pfe:NotesDue20271.000Member2023-08-012023-08-01
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): August 1, 2023
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 1, 2023, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated August 1, 2023, reporting Pfizer’s financial results for the second quarter of 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated August 1, 2023, reporting Pfizer’s financial results for the second quarter of 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: August 1, 2023
May 2, 2023
pfe-202305020000078003false00000780032023-05-022023-05-020000078003us-gaap:CommonStockMember2023-05-022023-05-020000078003pfe:NotesDue20271.000Member2023-05-022023-05-02
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): May 2, 2023
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
66 Hudson Boulevard East10001-2192 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 2, 2023, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated May 2, 2023, reporting Pfizer’s financial results for the first quarter of 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated May 2, 2023, reporting Pfizer’s financial results for the first quarter of 2023.
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: May 2, 2023
Jan 31, 2023
pfe-202301310000078003false00000780032023-01-312023-01-310000078003us-gaap:CommonStockMember2023-01-312023-01-310000078003pfe:NotesDue20271.000Member2023-01-312023-01-31
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): January 31, 2023
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
235 East 42nd Street10017 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On January 31, 2023, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2022. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated January 31, 2023, reporting Pfizer’s financial results for fourth-quarter and full-year 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated January 31, 2023, reporting Pfizer’s financial results for fourth-quarter and full-year 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: January 31, 2023
Nov 1, 2022
pfe-202211010000078003false00000780032022-11-012022-11-010000078003us-gaap:CommonStockMember2022-11-012022-11-010000078003pfe:NotesDue20271.000Member2022-11-012022-11-01
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): November 1, 2022
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
235 East 42nd Street10017 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
On November 1, 2022, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2022. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated November 1, 2022, reporting Pfizer’s financial results for the third quarter of 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated November 1, 2022, reporting Pfizer’s financial results for the third quarter of 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: November 1, 2022
Jul 28, 2022
pfe-202207280000078003false00000780032022-07-282022-07-280000078003us-gaap:CommonStockMember2022-07-282022-07-280000078003pfe:NotesDue20271.000Member2022-07-282022-07-28
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): July 28, 2022
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
235 East 42nd Street10017 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
On July 28, 2022, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2022. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated July 28, 2022, reporting Pfizer’s financial results for the second quarter of 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated July 28, 2022, reporting Pfizer’s financial results for the second quarter of 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: July 28, 2022
May 3, 2022
pfe-202205030000078003false00000780032022-05-032022-05-030000078003us-gaap:CommonStockMember2022-05-032022-05-030000078003pfe:NotesDue20271.000Member2022-05-032022-05-03
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): May 3, 2022
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
235 East 42nd Street10017 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 3, 2022, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2022. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated May 3, 2022, reporting Pfizer’s financial results for the first quarter of 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated May 3, 2022, reporting Pfizer’s financial results for the first quarter of 2022. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: May 3, 2022
Apr 20, 2022
pfe-202204200000078003false00000780032022-04-202022-04-200000078003us-gaap:CommonStockMember2022-04-202022-04-200000078003pfe:NotesDue20271.000Member2022-04-202022-04-20
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): April 20, 2022
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
235 East 42nd Street10017 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
As discussed in the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2021 Annual Report on Form 10-K, non-GAAP Adjusted income is an alternative measure of performance used by Pfizer Inc. (the “Company” or “we”) management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations––the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide––prior to considering certain income statement elements.
After consultation with the Staff of the U.S. Securities and Exchange Commission, beginning in the first quarter of 2022, we will begin including the following expenses in our non-GAAP Adjusted income: (a) all acquired in-process research and development costs incurred in connection with upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities, and (b) asset acquisitions of acquired in-process research and development. Prior to this change, certain of these items were excluded from our non-GAAP adjusted results. We expect the impact of this change in our non-GAAP financial measure will reduce our Adjusted income and Adjusted diluted EPS for the first quarter of 2022 by approximately $275 million, and $0.05, respectively, although the Company has not yet finalized its results for the period and therefore actual amounts could differ from those the Company currently anticipates. These first quarter of 2022 amounts may not be indicative of similar costs which may be incurred in connection with any future acquired in process research and development. In the first quarter of 2022, we will begin reporting in our earnings release and Form 10-Q Acquired in-process research and development expenses as a separate line item in our consolidated statements of income. We will recast prior periods to conform to this new presentation. Also in the first quarter of 2022, we will begin to include in full-year financial guidance the impact of acquired in-process research and development expenses incurred in the current quarter, or expected to be incurred for transactions signed through a defined date, but will not include any impact for acquired in-process research and development expenses which may be incurred in connection with potential business development activities entered after that time. We plan to post our recasted unaudited GAAP to non-GAAP reconciliations for each quarter of 2021, as well as for full
Feb 8, 2022
pfe-202202080000078003false00000780032022-02-082022-02-080000078003us-gaap:CommonStockMember2022-02-082022-02-080000078003pfe:NotesDue20220.250Member2022-02-082022-02-080000078003pfe:NotesDue20271.000Member2022-02-082022-02-08
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of report (Date of earliest event reported): February 8, 2022
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170 (State or other(Commission File(I.R.S. Employer jurisdiction ofNumber)Identification No.) incorporation)
235 East 42nd Street10017 New York, New York (Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 733-2323
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $.05 par valuePFENew York Stock Exchange 0.250% Notes due 2022PFE22New York Stock Exchange 1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 8, 2022, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2021. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberExhibit Description
Exhibit 99 Press Release of Pfizer Inc. dated February 8, 2022, reporting Pfizer’s financial results for fourth-quarter and full-year 2021. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Exhibit No.Description
99 Press Release of Pfizer Inc. dated February 8, 2022, reporting Pfizer’s financial results for fourth-quarter and full-year 2021. 104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel
Dated: February 8, 2022
This page provides Pfizer Inc. (PFE) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on PFE's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.